GLUE Monte Rosa Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1826457 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-61.3%
TTM net income YoY-725.3%
TTM EPS YoY-574.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-214.5%
Net margin-186.2%
FCF margin-248.0%
EBITDA margin-202.8%
Returns
ROE-35.3%
ROA-22.6%
ROIC (approx.)-48.8%
Asset turnover0.12x
Leverage & solvency
Liabilities / assets28.9%
Debt / equity0.00x
Current ratio10.32x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.26x
Accruals ratio6.0%
Payout ratio—
Capex / revenue12.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $123.67M | $75.62M | $0 | — | — |
| R&D expense | $141.50M | $121.56M | $111.27M | $85.06M | $57.16M |
| SG&A expense | $36.38M | $35.17M | $32.04M | $27.32M | $15.73M |
| Operating income | -$54.21M | -$81.11M | -$143.31M | -$112.38M | -$72.88M |
| Pretax income | -$39.72M | -$70.13M | -$135.01M | -$108.50M | -$9.88M |
| Income tax | -$1.10M | $2.57M | $338,000 | $0 | — |
| Net income | -$38.63M | -$72.70M | -$135.35M | -$108.50M | -$73.96M |
| EBITDA | -$45.85M | -$72.99M | -$137.09M | -$108.64M | -$70.75M |
| EPS (basic) | — | — | — | — | -2.96 |
| EPS (diluted) | — | — | — | — | -2.96 |
| Weighted avg. shares (diluted) | 83.07M | 73.91M | 51.40M | 47.23M | 25.00M |
| Balance sheet | |||||
| Cash & equivalents | $129.88M | $229.12M | $132.68M | $60.19M | $351.41M |
| Current assets | $393.19M | $377.44M | $236.21M | $275.89M | $348.67M |
| PP&E, net | $25.99M | $29.48M | $33.80M | $27.07M | $12.32M |
| Total assets | $448.66M | $438.73M | $303.75M | $342.39M | $366.33M |
| Current liabilities | $64.21M | $156.95M | $46.59M | $25.57M | $16.64M |
| Total liabilities | $215.60M | $215.80M | $124.50M | $70.98M | $18.81M |
| Shareholders' equity | $233.06M | $222.94M | $179.25M | $271.41M | $347.51M |
| Shares outstanding | 65.54M | 61.51M | 50.14M | 49.32M | 46.54M |
| Cash flow statement | |||||
| Operating cash flow | -$22.80M | $42.00M | -$43.80M | -$92.47M | -$59.36M |
| Capital expenditure | $4.70M | $3.99M | $19.04M | $12.91M | $9.73M |
| Free cash flow | -$27.50M | $38.01M | -$62.84M | -$105.38M | -$69.09M |
| Investing cash flow | -$101.83M | -$44.45M | $88.80M | -$219.22M | -$9.65M |
| Financing cash flow | $30.35M | $98.89M | $27.49M | $20.47M | $377.56M |
| Depreciation & amortization | $8.36M | $8.12M | $6.22M | $3.75M | $2.13M |
| Stock-based compensation | $18.86M | $18.13M | $16.67M | $11.66M | $5.20M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.